Radiopharmaceuticals
Discovery and development of radioligands, targeting vectors, chelators and new radiochemistry.
Research insight platform
Following the frontier of nuclear medicine.
追踪全球与中国核医学前沿
XNucMed follows the latest advances in research, development and clinical application of nuclear medicine — from β-emitting radioligand therapy to molecular imaging and isotope supply — across the world and in China.
X stands for any emitter: β⁻ for today’s radioligand therapy, α and Auger for what comes next.
What we follow
Six areas shaping the field
We track the science, the pipeline and the policy that move nuclear medicine from the laboratory to the clinic.
Theranostics
Paired diagnostic and therapeutic agents — "see what you treat" — and the evidence behind targeted radionuclide therapy.
Molecular imaging
PET, SPECT and hybrid systems, total-body scanners, novel tracers and AI-assisted image analysis.
Isotope supply
Reactors, cyclotrons and generators; production capacity, supply chains and the race for scarce isotopes.
Clinical trials & approvals
Trial readouts, regulatory milestones and real-world adoption across major markets.
Industry & policy
Deals, financing, manufacturing build-outs, reimbursement and the policy frameworks that shape access.
Radionuclides in focus
The radionuclides behind the headlines
β⁻ emitters power today’s radioligand therapy, α emitters are coming next — and every therapy relies on imaging to see what it treats.
Therapy β⁻ today, α next
β⁻177Lu
Radioligand therapy workhorse for PSMA and SSTR targets; its γ emissions allow post-therapy imaging
β⁻90Y
High-energy β⁻ emitter used for radioembolization of liver tumours
β⁻131I
Long-established therapy for thyroid disease and cancer
α · next225Ac
Alpha emitter for next-generation targeted therapy
Imaging see what you treat
β⁺ PET68Ga
Generator-based PET companion for PSMA and SSTR therapy
β⁺ PET18F
Cyclotron-produced PET tracers such as FDG and PSMA agents
β⁺ PET64Cu
Longer-lived PET; theranostic partner of β⁻-emitting ⁶⁷Cu
γ SPECT99mTc
SPECT workhorse, generator-produced from Mo-99
Two lenses
A global view, with depth on China
China is one of the fastest-developing nuclear medicine markets in the world. We connect what happens there to the global picture — and back.
Global
Worldwide advances
- Pivotal trials and approvals in β-emitter radioligand therapy
- New targets and vectors, and the next wave of α-emitter programs
- Isotope production capacity and supply-chain resilience
- Guidelines and practice updates from leading societies
China · 中国
Developments in China
- Domestic medical isotope production and long-term planning
- NMPA registrations and innovative radiopharmaceutical pipelines
- PET/SPECT installation growth and hospital department build-out
- Academic output, partnerships and cross-border licensing
Insights
Explore by topic
From first principles to the latest papers, deals and technology — every article belongs to one core topic.
NucMed 101
The fundamentals of nuclear medicine — physics, radionuclides, imaging and therapy — explained from first principles.
1 article →Research
Plain-language explanations of key papers from The Journal of Nuclear Medicine and other leading journals.
Coming soonIndustry
Companies, deals, manufacturing, supply chains and the regulatory landscape shaping radiopharmaceuticals.
Coming soonTechnology
Advances in scanners, radiochemistry, isotope production, dosimetry and AI that change what is possible.
Coming soonInvestment
Market and investment perspectives on the radiopharmaceutical and nuclear medicine sector.
Coming soon